-
Something wrong with this record ?
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
N. Papakonstantinou, S. Ntoufa, M. Tsagiopoulou, T. Moysiadis, S. Bhoi, A. Malousi, F. Psomopoulos, L. Mansouri, S. Laidou, D. Papazoglou, M. Gounari, K. Pasentsis, K. Plevova, V. Kuci-Emruli, M. Duran-Ferrer, Z. Davis, S. Ek, D. Rossi, G....
Language English Country United States
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
Grant support
NV15-30015A
MZ0
CEP Register
PubMed
30447004
DOI
10.1002/ijc.31999
Knihovny.cz E-resources
- MeSH
- Apoptosis genetics MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell blood genetics pathology MeSH
- Epigenomics methods MeSH
- Humans MeSH
- RNA, Small Interfering metabolism MeSH
- DNA Methylation genetics MeSH
- Tumor Cells, Cultured MeSH
- Tumor Suppressor Proteins genetics metabolism MeSH
- Primary Cell Culture MeSH
- Promoter Regions, Genetic genetics MeSH
- Receptors, Antigen, B-Cell metabolism MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- Sequence Analysis, RNA MeSH
- Gene Expression Profiling methods MeSH
- Transcription Factors genetics metabolism MeSH
- Up-Regulation MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Chronic lymphocytic leukemia (CLL) stereotyped subsets #6 and #8 include cases expressing unmutated B cell receptor immunoglobulin (BcR IG) (U-CLL). Subset #6 (IGHV1-69/IGKV3-20) is less aggressive compared to subset #8 (IGHV4-39/IGKV1(D)-39) which has the highest risk for Richter's transformation among all CLL. The underlying reasons for this divergent clinical behavior are not fully elucidated. To gain insight into this issue, here we focused on epigenomic signatures and their links with gene expression, particularly investigating genome-wide DNA methylation profiles in subsets #6 and #8 as well as other U-CLL cases not expressing stereotyped BcR IG. We found that subset #8 showed a distinctive DNA methylation profile compared to all other U-CLL cases, including subset #6. Integrated analysis of DNA methylation and gene expression revealed significant correlation for several genes, particularly highlighting a relevant role for the TP63 gene which was hypomethylated and overexpressed in subset #8. This observation was validated by quantitative PCR, which also revealed TP63 mRNA overexpression in additional nonsubset U-CLL cases. BcR stimulation had distinct effects on p63 protein expression, particularly leading to induction in subset #8, accompanied by increased CLL cell survival. This pro-survival effect was also supported by siRNA-mediated downregulation of p63 expression resulting in increased apoptosis. In conclusion, we report that DNA methylation profiles may vary even among CLL patients with similar somatic hypermutation status, supporting a compartmentalized approach to dissecting CLL biology. Furthermore, we highlight p63 as a novel prosurvival factor in CLL, thus identifying another piece of the complex puzzle of clinical aggressiveness.
2nd Medical Department University Hospital Schleswig Holstein Kiel Germany
Department of Haematology Royal Bournemouth Hospital Bournemouth UK
Department of Immunotechnology Faculty of Engineering Lund University Sweden
Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece
Hematology Department and University Pierre et Marie Curie Paris France
Hematology Department Nikea General Hospital Athens Greece
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034898
- 003
- CZ-PrNML
- 005
- 20201101165352.0
- 007
- ta
- 008
- 191007s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.31999 $2 doi
- 035 __
- $a (PubMed)30447004
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Papakonstantinou, Nikos $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 245 10
- $a Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia / $c N. Papakonstantinou, S. Ntoufa, M. Tsagiopoulou, T. Moysiadis, S. Bhoi, A. Malousi, F. Psomopoulos, L. Mansouri, S. Laidou, D. Papazoglou, M. Gounari, K. Pasentsis, K. Plevova, V. Kuci-Emruli, M. Duran-Ferrer, Z. Davis, S. Ek, D. Rossi, G. Gaidano, M. Ritgen, D. Oscier, N. Stavroyianni, S. Pospisilova, F. Davi, P. Ghia, A. Hadzidimitriou, C. Belessi, JI. Martin-Subero, C. Pott, R. Rosenquist, K. Stamatopoulos,
- 520 9_
- $a Chronic lymphocytic leukemia (CLL) stereotyped subsets #6 and #8 include cases expressing unmutated B cell receptor immunoglobulin (BcR IG) (U-CLL). Subset #6 (IGHV1-69/IGKV3-20) is less aggressive compared to subset #8 (IGHV4-39/IGKV1(D)-39) which has the highest risk for Richter's transformation among all CLL. The underlying reasons for this divergent clinical behavior are not fully elucidated. To gain insight into this issue, here we focused on epigenomic signatures and their links with gene expression, particularly investigating genome-wide DNA methylation profiles in subsets #6 and #8 as well as other U-CLL cases not expressing stereotyped BcR IG. We found that subset #8 showed a distinctive DNA methylation profile compared to all other U-CLL cases, including subset #6. Integrated analysis of DNA methylation and gene expression revealed significant correlation for several genes, particularly highlighting a relevant role for the TP63 gene which was hypomethylated and overexpressed in subset #8. This observation was validated by quantitative PCR, which also revealed TP63 mRNA overexpression in additional nonsubset U-CLL cases. BcR stimulation had distinct effects on p63 protein expression, particularly leading to induction in subset #8, accompanied by increased CLL cell survival. This pro-survival effect was also supported by siRNA-mediated downregulation of p63 expression resulting in increased apoptosis. In conclusion, we report that DNA methylation profiles may vary even among CLL patients with similar somatic hypermutation status, supporting a compartmentalized approach to dissecting CLL biology. Furthermore, we highlight p63 as a novel prosurvival factor in CLL, thus identifying another piece of the complex puzzle of clinical aggressiveness.
- 650 _2
- $a apoptóza $x genetika $7 D017209
- 650 _2
- $a metylace DNA $x genetika $7 D019175
- 650 _2
- $a epigenomika $x metody $7 D057890
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a stanovení celkové genové exprese $x metody $7 D020869
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x krev $x genetika $x patologie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a primární buněčná kultura $7 D061251
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 650 _2
- $a malá interferující RNA $x metabolismus $7 D034741
- 650 _2
- $a receptory antigenů B-buněk $x metabolismus $7 D011947
- 650 _2
- $a sekvenční analýza RNA $7 D017423
- 650 _2
- $a transkripční faktory $x genetika $x metabolismus $7 D014157
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 650 _2
- $a nádorové supresorové proteiny $x genetika $x metabolismus $7 D025521
- 650 _2
- $a upregulace $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ntoufa, Stavroula $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Tsagiopoulou, Maria $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Moysiadis, Theodoros $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Bhoi, Sujata $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Malousi, Andigoni $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Laboratory of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, Greece.
- 700 1_
- $a Psomopoulos, Fotis $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Mansouri, Larry $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Laidou, Stamatia $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Papazoglou, Despoina $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Gounari, Maria $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Pasentsis, Konstantinos $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Plevova, Karla $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty of the Masaryk University, Brno, Czech republic.
- 700 1_
- $a Kuci-Emruli, Venera $u Department of Immunotechnology, Faculty of Engineering, Lund University, Sweden.
- 700 1_
- $a Duran-Ferrer, Marti $u Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Departamento de Fundamentos Clínicos, Universitat de Barcelona, Barcelona, Spain.
- 700 1_
- $a Davis, Zadie $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
- 700 1_
- $a Ek, Sara $u Department of Immunotechnology, Faculty of Engineering, Lund University, Sweden.
- 700 1_
- $a Rossi, Davide $u Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.
- 700 1_
- $a Gaidano, Gianluca $u Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
- 700 1_
- $a Ritgen, Matthias $u Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Oscier, David $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
- 700 1_
- $a Stavroyianni, Niki $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
- 700 1_
- $a Pospisilova, Sarka $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty of the Masaryk University, Brno, Czech republic.
- 700 1_
- $a Davi, Frederic $u Hematology Department and University Pierre et Marie Curie, Paris, France.
- 700 1_
- $a Ghia, Paolo $u Division of Experimental Oncology, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy.
- 700 1_
- $a Hadzidimitriou, Anastasia $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
- 700 1_
- $a Belessi, Chrysoula $u Hematology Department, Nikea General Hospital, Athens, Greece.
- 700 1_
- $a Martin-Subero, Jose I $u Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Departamento de Fundamentos Clínicos, Universitat de Barcelona, Barcelona, Spain.
- 700 1_
- $a Pott, Christiane $u Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Rosenquist, Richard $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Stamatopoulos, Kostas $u Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 144, č. 11 (2019), s. 2695-2706
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30447004 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20201101165351 $b ABA008
- 999 __
- $a ok $b bmc $g 1451558 $s 1073448
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 144 $c 11 $d 2695-2706 $e 20190115 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- GRA __
- $a NV15-30015A $p MZ0
- LZP __
- $a Pubmed-20191007
